A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire
POMAQ
2 other identifiers
observational
54
1 country
1
Brief Summary
The purpose of this study is to evaluate the patient usability and reliability of the POMAQ survey to evaluate opioid misuse and abuse among adults with chronic moderate to severe pain, including patients who are opioid abusers, non-abusers, as well as non-opioid users
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2015
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 2, 2015
CompletedFirst Submitted
Initial submission to the registry
January 14, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 18, 2016
CompletedFirst Posted
Study publicly available on registry
January 21, 2016
CompletedApril 15, 2020
April 1, 2020
1 year
January 14, 2016
April 14, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Content validity of POMAQ
Evidence of content validity from patients regarding the interpretation of POMAQ items, ease of completion, the comprehensiveness of instrument, and the appropriateness of the format, response scales, and recall period
Day 1, based upon survey completed at single visit
Study Arms (4)
Group 1: Opioid abusers
Group 2: Abusers of other substances
Group 3: Non-opioid abusers
Group 4: Non-opioid users
Interventions
Eligibility Criteria
Patients with chronic pain recruited from primary care or chronic pain clinics
You may qualify if:
- Age ≥ 18 years
- Patients who, based on the Site Investigator's clinical judgment, have chronic moderate to severe pain
- Willing to provide written informed consent
- Able to participate in a one-on-one interview
- Able to read, speak, and understand English and complete all study assessments.
You may not qualify if:
- Cognitive, psychiatric or other impairment based on the Site Investigator's clinical judgment that would interfere with participating in a one-on-one discussion
- Terminal illness with life expectancy \< 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Member Companies of the Opioid PMR Consortiumlead
- Evideracollaborator
Study Sites (1)
Evidera
Bethesda, Maryland, 20814, United States
Related Publications (1)
Coyne KS, Schnoll SH, Butler SF, Barsdorf AI, Currie BM, Maziere JY, Pierson RF, Porter LN, Franks CMJ Jr, Farrar JT. Clinical scoring algorithm for the prescription opioid misuse and abuse questionnaire (POMAQ). Curr Med Res Opin. 2022 Jun;38(6):971-980. doi: 10.1080/03007995.2022.2065139. Epub 2022 May 13.
PMID: 35437075DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Alexandra Barsdorf, Ph.D.
Pfizer
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 14, 2016
First Posted
January 21, 2016
Study Start
January 2, 2015
Primary Completion
January 18, 2016
Study Completion
January 18, 2016
Last Updated
April 15, 2020
Record last verified: 2020-04